BUSINESS COMBINATIONS Business Combinations in Fiscal Year 2019 Cancer Treatment Services International In June 2019, the Company acquired Cancer Treatment Services International ("CTSI"), a privately-held company that provides cancer care professional services to health care providers worldwide and, through its oncology care brand, American Oncology Institute, focuses on the operation of comprehensive cancer treatment facilities in international markets. CTSI operates AmPath, a full-service reference laboratory and pathology provider, and CTSI Oncology Solutions, an oncology services company that provides solutions such as remote treatment planning services and multi-disciplinary oncology consulting. This acquisition will increase the Company's expertise in cancer center operations. The Company acquired CTSI for a purchase price of $279.3 million , consisting of $262.8 million of cash consideration, $8.2 million of contingent consideration, and $8.3 million of other consideration. The undiscounted range of the contingent consideration payments is zero to $58 million and is based on actual revenues over the 18 months following the acquisition date. The acquisition was financed with a combination of cash on hand and proceeds from borrowings. The Company has included this acquisition in its Oncology Systems business. The purchase accounting from this transaction is not yet finalized; however, the goodwill is not expected to be deductible for income tax purposes. Endocare and Alicon In June 2019, the Company acquired Austin, Texas-based Endocare and Hangzhou, China-based, Alicon, to expand its portfolio of multidisciplinary integrated cancer solutions. Endocare is a leading provider of hardware and software solutions for cryoablation, and has a microwave ablation product line; and Alicon is a leader in embolic therapy for treating liver cancer in China. These acquisitions enable the Company to develop innovations in interventional oncology and allow it to provide patients and customers with a wider range of cancer care solutions. The Company acquired Endocare and Alicon for a combined purchase price of $209.4 million consisting of $196.8 million of cash consideration and $12.6 million of contingent consideration. The undiscounted range of the contingent consideration payments is zero to $40 million and is based on actual revenues through March 2020. The acquisitions were financed with a combination of cash on hand and proceeds from borrowings. These acquisitions comprise the Company's Interventional Oncology business, which is reflected in the "Other" category because the operating segment does not meet the criteria for a reportable operating segment. The purchase accounting from this transaction is not yet finalized; however, the goodwill is not expected to be deductible for income tax purposes. The results of operations and the provisional fair values of the assets acquired and liabilities assumed have been included in the condensed consolidated financial statements as of the date of acquisition. The following table summarizes the estimated fair value of assets acquired and liabilities assumed as a result of the CTSI, Endocare and Alicon acquisitions: (In millions) CTSI Endocare and Alicon Assets acquired (1) $ 54.0 $ 32.9 Liabilities assumed (2) (65.0 ) (17.7 ) Goodwill 182.1 122.7 Intangible assets 117.0 71.5 Fair value of net assets 288.1 209.4 Less: Non-controlling interest (3) 8.8  Total purchase consideration $ 279.3 $ 209.4 (1) Includes $5.4 million and $11.5 million of cash and cash equivalents for CTSI and Endocare / Alicon, respectively. (2) Includes $33.9 million and $14.8 million of deferred tax liabilities for CTSI and Endocare / Alicon, respectively. (3) The Company's non-controlling interest is a joint venture that was determined to be a variable interest entity. The Company has concluded that it is the primary beneficiary of the joint venture because it has the ability to control the significant activities of the joint venture, has the right to significant residual returns and is exposed to significant expected losses. The Company will consolidate the joint venture into its operations. Identifiable Intangible Assets The following table provides the valuation of the intangible assets acquired from CTSI, Endocare and Alicon, along with their estimated useful lives: (Dollars in millions) CTSI Endocare and Alicon Type Fair Value Weighted Average Estimated Useful Life (In Years) Fair Value Weighted Average Estimated Useful Life (In Years) Technologies and trade names $ 47.9 10.7 $ 56.3 7.7 Customer contracts, supplier relationships, and partner relationships (1) 69.1 26.4 4.8 3.0 Total intangible assets with finite lives 117.0 61.1 In-process research and development with indefinite lives  10.4 Total intangible assets $ 117.0 $ 71.5 (1) CTSI has certain partner relationships with hospitals with useful lives that range from approximately 27 to 29 years. Other Acquisitions In the third quarter of fiscal year 2019, the Company purchased a privately-held company for a cash purchase price of $15.2 million , including a holdback of $3.6 million and contingent consideration. As of the closing date, the value of the contingent consideration is zero because none of the milestones were probable to be achieved. However, the Company could potentially pay up to approximately $9 million by 2023 if certain milestones were met plus additional payments for achieving revenue targets through 2035. The acquisition was classified as an asset acquisition, a nd the purchase consideration was allocated primarily to the intellectual property that covers the use of radiation in the heart and other forms of radiosurgery for cardiovascular disease, resulting in a $20.8 million of in-process research and development ("in-process R&amp;D") expense because of no future alternative use, and was recorded in acquisition-related expenses and in-process R&amp;D in the Condensed Consolidated Statements of Earnings. In the first quarter of fiscal year 2019, the Company acquired a privately-held software company for a purchase price of $28.5 million . The acquisition primarily consisted of $22.0 million in goodwill and $6.5 million in finite-lived intangible assets. The Company has integrated this acquisition into its Oncology Systems reporting unit. The goodwill for this acquisition is not deductible for income tax. Measurement Period Adjustments In the first quarter of fiscal year 2019, the Company recorded a measurement period adjustment of $9.6 million to the fair value of the purchase consideration of a business combination that occurred in the fourth quarter of fiscal year 2018. The adjustment primarily included a $11.9 million decrease in the fair value of the contingent consideration liability mostly offset by a decrease to the finite-lived intangible assets of $5.4 million , and a decrease of $4.7 million to goodwill. In the third quarter of fiscal year 2019, the Company recorded a measurement period adjustment of $2.6 million to the fair value of the purchase consideration of a business combination that occurred in the third quarter of fiscal year 2018. The adjustment consisted of an additional cash payment to sellers and a corresponding increase to goodwill. Other Information The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount. The Company believes the factors that contributed to goodwill in its completed acquisitions include synergies not available to market participants, as well as the acquisition of a talented workforce. The fair value of assets acquired and liabilities assumed has been determined on a preliminary basis, and the Company will finalize these amounts as it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the date of a business combination may result in certain adjustments. The Company expects to finalize these amounts no later than one year from the date of each business combination. Management applied significant judgment in determining the fair value of intangible assets, which involved the use of significant estimates and assumptions with respect to the revenue growth rates, the economic lives, and the discount rates. The fair value of the contingent consideration has been estimated based on the likelihood of the performance metrics being achieved. The condensed consolidated financial statements include the operating results from the date the business was acquired. The impact of the completed business combinations to the periods presented was not material. Pro forma results of operations for the completed business combination have not been presented because the effects were not material to the Company's condensed consolidated financial statements. The Company incurred acquisition-related expenses of $10.4 million and $12.7 million during the three months ended June 28, 2019 and June 29, 2018 , respectively, and $15.0 million and $33.9 million during the nine months ended June 28, 2019 and June 29, 2018 , respectively.